Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Aug 15, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	10,000	$179.13	68,470
Aug 15, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	10,000	--	10,000
May 16, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	10,000	$179.13	68,470
May 16, 2022	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	10,000	--	20,000
Dec 11, 2019	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	10,000	--	57,951
Dec 08, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	11,473	--	11,473
Jul 13, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	13,000	$30.63	54,951
Jul 13, 2020	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	13,000	--	13,736
Dec 04, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,464	$813.58	65,957
Nov 13, 2023	MURPHY ANDREW J EVP Research	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,508	$795.69	65,913

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media